| A dual orexin receptor antagonist is being developed by Idorsia Pharmaceuticals Ltd. for the treatment of insomnia. |
| Received its first approval on January 7 2022 in the USA. |
| Approved for use in adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.